Macular Degeneration Trial, Recruiting (NCT06375239)

Macular Degeneration Trial, Recruiting NCT06375239 Sponsor: Ray Therapeutics, Inc. Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT06375239 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a retinal condition such as retinitis pigmentosa (in both eyes), choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis, or another inherited retinal disease, confirmed by past eye exam records
Your best vision (with glasses or contacts if needed) in at least one eye falls within a certain range — not fully clear but not completely without light perception — specifically between 20/70 and being able to only see a hand moving in front of the eye (confirm with trial site if unsure where your vision falls)
You can communicate reasonably well in English

Who may not be able to join:

You have a cognitive condition, significant memory loss, or dementia that would make it difficult to give informed consent or complete the study tasks
There is any other reason, in the opinion of the study doctor, that might make it hard for you to participate in or follow the study requirements (confirm with trial site)
You are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 949-264-3793

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06375239

Sponsor: Ray Therapeutics, Inc.

Phase: Not Applicable

Status: Recruiting

Condition: Macular Degeneration

Trial contact: 949-264-3793

More information: https://clinicaltrials.gov/study/NCT06375239

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a retinal condition such as retinitis pigmentosa (in both eyes), choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis, or another inherited retinal disease, confirmed by past eye exam records
Your best vision (with glasses or contacts if needed) in at least one eye falls within a certain range — not fully clear but not completely without light perception — specifically between 20/70 and being able to only see a hand moving in front of the eye (confirm with trial site if unsure where your vision falls)
You can communicate reasonably well in English

Who may not be able to join:

You have a cognitive condition, significant memory loss, or dementia that would make it difficult to give informed consent or complete the study tasks
There is any other reason, in the opinion of the study doctor, that might make it hard for you to participate in or follow the study requirements (confirm with trial site)
You are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ray Therapeutics, Inc.

Registry

ClinicalTrials.gov

Start date

5 April 2024

Est. completion

30 April 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov